RQ Bio Secures $115 Million to Accelerate Clinical Development of RQB01, a Long-Acting Influenza Prevention Antibody
Strategic Rationale Behind Funding and Expectations of Investors
RQ Bio, a UK-based biotechnology company, has successfully raised $115 million (approximately ₩160 billion) in a Series A funding round. The investment was led by Frazier Life Sciences, with participation from EQT Life Sciences and Forbion, garnering significant attention within the industry. This reflects not only a financial investment but also a strong market recognition of the commercial value of RQ Bio's long-acting antibody-based influenza prevention technology. The secured funds will be instrumental in advancing the lead candidate into clinical trials and expanding the pipeline.
Technological Innovation and the Differentiated Mechanism of RQB01
RQB01, RQ Bio's core asset, is a long-acting monoclonal antibody therapeutic that targets conserved epitopes of the influenza virus. This antibody is designed to provide resilience against the genetic variations of influenza viruses, aiming to offer sustained protection for an entire season with a single administration. The success of Sipavibart/Kavigale, an influenza prevention antibody developed by AstraZeneca and approved by the EMA and PMDA, which was based on RQ Bio's proprietary antibody discovery platform, further validates the reliability of this technology. Notably, RQB01 has the potential to provide a groundbreaking preventive option for immunocompromised patients and high-risk individuals with poor vaccine responses.
Paradigm Shift in Influenza Prevention Market and Market Size
The global influenza vaccine market is currently estimated at $7.6 billion to $9.2 billion by 2025 and is projected to exceed $17.4 billion by 2035. Moderna's mRNA-based influenza vaccine, mFlusiva, a leading player in the vaccine market, received a positive recommendation for approval from the FDA Advisory Committee in June 2026, signaling a potential shift away from traditional egg- and cell-based vaccines. In response, antibody-based preventatives like those from RQ Bio are focusing on high-risk patient populations with poor immune responses, expanding the influenza prevention paradigm from a vaccine-centric approach to a combined therapeutic and preventive market. This represents a future growth area with the potential for intense competition for market share with vaccine platforms.
Critical Juncture for Clinical Entry and Competitive Landscape
The secured investment will be primarily allocated to completing the preclinical research required for submitting an Investigational New Drug (IND) application and initiating the first-in-human clinical trial (Phase 1) planned for 2027. The most significant competitor in the market is Cidara Therapeutics' long-acting antiviral agent, CD388 (MK-1406), which gained a strong ally when Merck & Co. acquired Cidara for approximately $9.2 billion in January 2026. RQ Bio has now entered a critical period where it must rapidly build its clinical infrastructure and narrow the gap in clinical speed compared to its competitors through this significant capital injection. The safety and efficacy data from the upcoming Phase 1 trial will be a key indicator of the company's value and the technological maturity of its product.
RQ Bio's RQB01 is in the IND-enabling research phase and is poised to initiate a Phase 1 clinical trial in 2027, backed by a $115 million Series A funding round. In the global influenza vaccine market, estimated at $7.6 billion to $9.2 billion, with Moderna's mFlusiva nearing FDA approval in August 2026, long-acting antibody-based solutions targeting high-risk populations hold significant potential for diversifying preventive medicine and capturing a niche market. The $9.2 billion acquisition of Cidara Therapeutics by Merck in January 2026 demonstrates the high commercial value of influenza prevention pipelines. The successful commercialization of Sipavibart (Kavigale), an influenza prevention antibody licensed to AstraZeneca, further enhances the credibility of RQ Bio's proprietary antibody discovery platform and increases the likelihood of early licensing agreements. In the long term, establishing a long-acting immune solution that protects against diverse influenza viruses could lead to significant reductions in healthcare costs for high-risk patients and drive a paradigm shift in preventive medicine.
Source: FierceBiotech (rss)